Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Galapagos ADR 1 News

    28,74 $ -0,07% -0,02 $
    In : 26,800 € | 20:35:41 Uhr Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A0YGNJ
    ISIN: US36315X1019
    US-Symbol: GLPG
    Typ: Aktie

    Galapagos ADR 1 News

    03.01.24 - PR Newswire
    BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets
    BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets PR Newswire
    06.11.23 - PR Newswire
    Landmark Bio Signs Multi-Year Agreement to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-Care
    Landmark Bio Signs Multi-​Year Agreement to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-​of-Care PR Newswire
    27.01.22 - PR Newswire
    Thinking about buying stock in Aridis Pharmaceuticals, Galapagos, Qualtrics, Clean Energy Fuels, or Mattel?
    Thinking about buying stock in Aridis Pharmaceuticals, Galapagos, Qualtrics, Clean Energy Fuels, or Mattel? PR Newswire
    12.03.21 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG PR Newswire
    03.03.21 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG PR Newswire
    03.03.21 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG PR Newswire
    10.12.20 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG PR Newswire
    10.12.20 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG PR Newswire
    23.11.20 - PR Newswire
    Selvita to acquire Fidelta from Galapagos
    Selvita to acquire Fidelta from Galapagos PR Newswire
    19.08.20 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG PR Newswire
    16.04.20 - PR Newswire
    Galapagos and Ryvu Announce Research Collaboration
    Galapagos and Ryvu Announce Research Collaboration PR Newswire
    24.10.18 - PR Newswire
    AbbVie to Assume Full Development and Commercial Control of Cystic Fibrosis Research Program
    AbbVie to Assume Full Development and Commercial Control of Cystic Fibrosis Research Program PR Newswire
    07.09.16 - The Motley Fool
    Die 5 bisher besten Maßnahmen von Gilead Sciences 2016
    Gilead Sciences (WKN:885823) scheint den Boden einfach nicht zu finden. Obwohl die Aktie schon jetzt spottbillig mit einem erwarteten Kurs-​Gewinn-Verhältnis von 6,8 ist (das ist ...
    14.05.15 - PR Newswire
    Bryan, Garnier & Co Announces the Successful $275m IPO for Galapagos NV, the Largest Nasdaq IPO of European Biotech
    Bryan, Garnier & Co Announces the Successful $275m IPO for Galapagos NV, the Largest Nasdaq IPO of European Biotech PR Newswire
    24.09.13 - PR Newswire
    AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies
    AbbVie and Galapagos to Co-​Develop Cystic Fibrosis Therapies PR Newswire
    17.05.13 - PR Newswire
    AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease
    AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease First selective JAK1 inhibitor to enter Phase 2 studies in Crohn's disease Galapagos to fund ...

    Newssuche

    Videos

    newspaper
    26.04.24 +10,71%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »